LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares U.S. Healthcare ETF tracks the performance of the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index. Click here ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...